Stock Warrants: How They Work and Why They Dilute

A stock warrant is a contract, issued by a company, that gives the holder the right to buy a set number of the company’s shares at a fixed price before an expiry date. Exercising a warrant creates new shares, which is why warrants matter for dilution. They are common in micro-cap financings, so retail investors in small companies run into them often.

How a warrant works

A warrant has a few terms, all stated in the warrant document.

• Underlying shares: how many shares the holder can buy.
• Exercise price (strike): what the holder pays per share.
• Term: when it expires, commonly several years after issue.
• Exercisable from: the date the holder can first exercise. Some are exercisable immediately.

The holder is never required to exercise. If the stock trades above the exercise price, exercising can be worthwhile. If the stock trades below it, the warrant may expire unexercised.

Illustration: a company with 20,000,000 shares sells 5,000,000 shares and, in the same deal, issues warrants to buy another 5,000,000 shares at $1.00 each, expiring in five years.

Event	Shares outstanding
Before the deal	20,000,000
After shares sold	25,000,000
If all warrants exercised for cash	30,000,000
Cash the company receives on full exercise	$5,000,000 (5,000,000 x $1.00)

The made-up numbers show the trade-off: exercise brings cash in and adds shares. The 5,000,000 warrant shares are 20% of the 25,000,000 shares outstanding after the offering, so potential dilution is larger than the headline share sale alone. See stock dilution.

Warrant features that change the math

Terms vary, so read the exhibit. These are the features that come up most.

• Cash vs cashless exercise. Cash exercise sends money to the company. Cashless (net) exercise delivers fewer shares and no cash.
• Pre-funded warrants. The holder has already paid most of the price; the exercise price is a nominal amount per share. They are sometimes used in place of common shares so a holder stays under an ownership percentage. The terms are in the warrant exhibit.
• Beneficial ownership blockers. Many warrants say the holder cannot exercise if doing so would take them above a stated percentage of outstanding shares, often written as a figure such as 4.99% or 9.99%. This links to SEC Rule 13d-3(d)(1)(i), under which a person is deemed the beneficial owner of shares they have the right to acquire within sixty days, including through exercise of any warrant. Blockers are contract terms, so check each warrant’s wording.
• Anti-dilution adjustments. Some warrants adjust the exercise price or number of shares for stock splits, and some for later sales at lower prices. Price-based resets (sometimes called ratchets) can increase dilution if the company later issues shares at a lower price. This is a term to look for, not a feature of all warrants.
• Redemption or call rights. Some warrants let the company force exercise or redeem them if the stock trades above a set price for a set period. This is also a contract term.
• Registered vs unregistered. Shares issued on exercise must either be registered with the SEC or sold under an exemption. This shows up in the filings described below.

How warrants differ from other instruments

	Warrant	Convertible note	Employee option
Issued by	Company	Company	Company
Creates new shares on use	Yes	Yes (on conversion)	Yes
Holder pays at exercise	Usually yes (unless cashless or pre-funded)	No; debt converts	Yes
Typical use	Attached to a financing	Debt financing	Pay for service

Investor.gov’s convertible securities page defines dilution as the reduction in earnings per share and proportional ownership that occurs when, for example, holders of convertible securities convert those securities into common stock. Warrant exercise has the same effect on share count. See convertible notes explained for the debt-side version.

How warrants fit with registration and exchange rules

Three rules often shape warrant deals.

Form S-3 sizing. A company that uses the “baby shelf” under General Instruction I.B.6 of Form S-3 can sell no more than one-third of its non-affiliate common equity value in 12 calendar months. Instruction 2 to I.B.6 says that for derivative securities convertible into or exercisable for common equity, the company calculates the aggregate market value of the underlying shares in place of the market value of the derivative securities. SEC staff confirmed in Question 116.24 that this applies to warrants even if they are not exercisable within 12 months. See shelf registration.

Resale registration. Staff Question 116.11 says that to use Form S-3 for a secondary offering of a warrant under General Instruction I.B.3, the warrants themselves need not be listed; the underlying common stock being listed or quoted is enough.

Exchange approval. Nasdaq Rule 5635(d) requires shareholder approval before a “20% Issuance” at a price below the “Minimum Price”, where a 20% Issuance covers the sale, issuance or potential issuance of common stock, or securities convertible into or exercisable for it, equal to 20% or more of the shares or voting power outstanding before the issuance. The rule excludes a “public offering” as defined in IM-5635-3. Warrants issued in private placements are therefore counted at their underlying share number. The Minimum Price is the lower of the Nasdaq Official Closing Price immediately before signing the binding agreement or the average Nasdaq Official Closing Price for the five trading days before signing.

What to check in the filings

• Form 8-K, Item 3.02. This item covers unregistered sales of equity securities, including warrants. No report is needed if sales since the last report total less than 1% of the shares outstanding of the class, or less than 5% for a smaller reporting company.
• Form 8-K, Item 1.01 and Exhibit 4 (or 10). A financing often files the form of warrant, securities purchase agreement and registration rights agreement as exhibits. The exhibit shows the exercise price, term, blockers, adjustments and cashless provisions.
• Prospectus supplement (424B) and S-1 or S-3. For registered offerings, the cover page and “Description of Securities” section state the warrant terms. The “Dilution” section compares the offering price to net tangible book value per share, a disclosure required in certain cases by Regulation S-K Item 506.
• 10-K and 10-Q equity footnotes. Look for the warrant table: number outstanding, weighted-average exercise price, expiry.
• Diluted EPS note. Compare basic and diluted weighted-average shares. When a company has a net loss, in-the-money warrants are commonly excluded from the diluted count; the note lists what was excluded.
• Schedule 13G/13D. Under Rule 13d-3(d)(1)(i), beneficial ownership includes shares a holder can acquire within 60 days, including by exercising warrants.
• Form 4. Officers, directors and 10% holders report warrant acquisitions and exercises in the derivative securities table.

On EDGAR, use full-text search for “warrant” in 8-Ks, or open the “Exhibits” tab on the 8-K index page.

Red flags vs normal

These are neutral observations about mechanics.

Feature	Often seen in	Why it matters to share count
Exercise price near or below market	Recent financings	Exercise is more likely, so dilution is nearer.
Exercise price far above market	Older financings	Exercise may never occur; the warrants may expire.
Price-reset (ratchet) feature	Some small-company financings	A later lower-priced issue can raise the share count and cut the exercise price.
Warrants larger than the share sale	Some offerings	Potential shares exceed the headline raise.
Repeated exercise price reductions	Amendments filed as 8-Ks	Each cut raises the chance of exercise.
Warrant liability on the balance sheet	Filers with certain terms	Changes in fair value can run through the income statement; read the note.

Questions to ask when you see warrants in a filing

1. How many underlying shares are there compared with shares outstanding today?
2. What is the exercise price relative to recent trading?
3. Do the terms include price resets or a cashless exercise right?
4. Are the underlying shares registered for resale yet?